It is plausible that monoallelic mutations in PALB2, CHEK2 and ATM could be associated with increased risk of cancers other than breast cancer, as has been observed for BRCA1 and BRCA2 and both ovarian and prostate cancers.14–17 However, with the exception of pancreatic cancer in PALB2 carriers, there is little evidence to support or refute the existence of such associations, although a few individually striking pedigrees have been observed.4, 8, 18–20. This evidence concerns the gene CHEK2 and prostate carcinoma.